APOE4-dependent association between metformin use and Alzheimer's disease-related cortical thickness in older adults with type 2 diabetes
Abstract
BackgroundMetformin has been proposed to have neuroprotective benefits, but its effects on AD-related brain changes remain unclear and may be influenced by apolipoprotein E ε4 (APOE4) genotype, a major genetic risk factor for AD.ObjectiveTo examine the association between metformin use and in vivo AD pathologies and to evaluate whether APOE4 status moderates these associations in older adults with type 2 diabetes mellitus (T2DM).MethodsThis cross-sectional study used baseline data from 76 non-demented older adults with T2DM (aged 55-90 years), who were enrolled in the Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease (KBASE). The participants underwent comprehensive clinical and neuropsychological assessment and multimodal neuroimaging, including global amyloid- β (Aβ) retention ([11C] PiB-PET), inferior temporal tau deposition ([18F] AV-1451 PET), AD-signature cortical thickness (AD-CT), and white matter hyperintensity (WMH) volume. Global cognition was assessed using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological battery.ResultsAmong 76 participants, 55 (72%) were metformin users and 21 (28%) were non-users. Metformin use was significantly associated with greater AD-CT, but not with Aβ, tau, or WMH volume. A significant interaction between metformin use and APOE4 status was observed with respect to AD-CT. In APOE4-stratified analyses, metformin use was significantly associated with greater AD-CT…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 76 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.